The pharmaceutical outsourcing giant Lonza has completed the expansion of its facilities in Visp, Valais. Thanks to this work, the company has new capacities for the production of antibody-drug conjugates (ADC).
This capacity increase underscores the strategic importance the company places on ADCs, Lonza wrote in a statement Wednesday.
The ADC market is set to experience solid growth, driven by growing demand for newer cancer therapies that are now better targeted. The company thus claims to be well positioned to take advantage of this trend.
/ATS
